nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—lung cancer—esophageal cancer	0.441	1	CtDrD
Crizotinib—MAP3K3—esophageal cancer	0.181	0.494	CbGaD
Crizotinib—MET—esophageal cancer	0.106	0.29	CbGaD
Crizotinib—ABL1—esophageal cancer	0.0671	0.183	CbGaD
Crizotinib—ABCB1—esophageal cancer	0.0124	0.0338	CbGaD
Crizotinib—Localised oedema—Capecitabine—esophageal cancer	0.000985	0.035	CcSEcCtD
Crizotinib—Gastrointestinal perforation—Capecitabine—esophageal cancer	0.000954	0.0338	CcSEcCtD
Crizotinib—Peripheral sensory neuropathy—Capecitabine—esophageal cancer	0.000871	0.0309	CcSEcCtD
Crizotinib—Polyneuropathy—Capecitabine—esophageal cancer	0.000764	0.0271	CcSEcCtD
Crizotinib—Hypophosphataemia—Cisplatin—esophageal cancer	0.000581	0.0206	CcSEcCtD
Crizotinib—Dysaesthesia—Capecitabine—esophageal cancer	0.000576	0.0204	CcSEcCtD
Crizotinib—Generalised oedema—Cisplatin—esophageal cancer	0.000568	0.0201	CcSEcCtD
Crizotinib—Febrile neutropenia—Cisplatin—esophageal cancer	0.000561	0.0199	CcSEcCtD
Crizotinib—Disorder sight—Capecitabine—esophageal cancer	0.000523	0.0186	CcSEcCtD
Crizotinib—Lymphopenia—Capecitabine—esophageal cancer	0.000486	0.0173	CcSEcCtD
Crizotinib—Balance disorder—Capecitabine—esophageal cancer	0.000455	0.0162	CcSEcCtD
Crizotinib—Hepatotoxicity—Cisplatin—esophageal cancer	0.000437	0.0155	CcSEcCtD
Crizotinib—Abscess—Cisplatin—esophageal cancer	0.000427	0.0151	CcSEcCtD
Crizotinib—Visual acuity reduced—Capecitabine—esophageal cancer	0.000418	0.0148	CcSEcCtD
Crizotinib—Febrile neutropenia—Capecitabine—esophageal cancer	0.000414	0.0147	CcSEcCtD
Crizotinib—Infection—Carboplatin—esophageal cancer	0.000408	0.0145	CcSEcCtD
Crizotinib—RPS6KB1—neck—esophageal cancer	0.000378	0.00646	CbGeAlD
Crizotinib—FER—bronchus—esophageal cancer	0.00037	0.00631	CbGeAlD
Crizotinib—BMPR1B—epithelium—esophageal cancer	0.000368	0.00627	CbGeAlD
Crizotinib—IKBKE—lymph node—esophageal cancer	0.000367	0.00626	CbGeAlD
Crizotinib—TNK1—bronchus—esophageal cancer	0.000366	0.00624	CbGeAlD
Crizotinib—BMPR1B—bronchus—esophageal cancer	0.000362	0.00618	CbGeAlD
Crizotinib—MAP4K1—bronchus—esophageal cancer	0.000362	0.00618	CbGeAlD
Crizotinib—Haemoglobin decreased—Capecitabine—esophageal cancer	0.000362	0.0128	CcSEcCtD
Crizotinib—IGF1R—epithelium—esophageal cancer	0.000361	0.00615	CbGeAlD
Crizotinib—Neuralgia—Capecitabine—esophageal cancer	0.000358	0.0127	CcSEcCtD
Crizotinib—DCLK1—trachea—esophageal cancer	0.000355	0.00607	CbGeAlD
Crizotinib—TIE1—epithelium—esophageal cancer	0.000351	0.00598	CbGeAlD
Crizotinib—PRKD1—lung—esophageal cancer	0.000351	0.00598	CbGeAlD
Crizotinib—MET—digestive system—esophageal cancer	0.000349	0.00596	CbGeAlD
Crizotinib—IGF1R—smooth muscle tissue—esophageal cancer	0.000347	0.00593	CbGeAlD
Crizotinib—STK3—bronchus—esophageal cancer	0.000345	0.00589	CbGeAlD
Crizotinib—TIE1—smooth muscle tissue—esophageal cancer	0.000338	0.00577	CbGeAlD
Crizotinib—PRKD3—lung—esophageal cancer	0.000337	0.00575	CbGeAlD
Crizotinib—TESK1—bronchus—esophageal cancer	0.000334	0.0057	CbGeAlD
Crizotinib—FER—trachea—esophageal cancer	0.000332	0.00566	CbGeAlD
Crizotinib—DSTYK—lung—esophageal cancer	0.000329	0.00561	CbGeAlD
Crizotinib—TNK1—trachea—esophageal cancer	0.000328	0.0056	CbGeAlD
Crizotinib—Body temperature increased—Carboplatin—esophageal cancer	0.000325	0.0115	CcSEcCtD
Crizotinib—Hepatotoxicity—Capecitabine—esophageal cancer	0.000322	0.0114	CcSEcCtD
Crizotinib—LTK—lung—esophageal cancer	0.000321	0.00549	CbGeAlD
Crizotinib—CASK—lung—esophageal cancer	0.000321	0.00549	CbGeAlD
Crizotinib—Fluid retention—Cisplatin—esophageal cancer	0.000321	0.0114	CcSEcCtD
Crizotinib—LIMK2—bronchus—esophageal cancer	0.000318	0.00542	CbGeAlD
Crizotinib—Neuropathy—Cisplatin—esophageal cancer	0.000317	0.0112	CcSEcCtD
Crizotinib—MAP3K12—bronchus—esophageal cancer	0.000314	0.00536	CbGeAlD
Crizotinib—ACVR1—bronchus—esophageal cancer	0.000314	0.00536	CbGeAlD
Crizotinib—MAPK7—lung—esophageal cancer	0.000311	0.00531	CbGeAlD
Crizotinib—TXK—lung—esophageal cancer	0.000311	0.00531	CbGeAlD
Crizotinib—FES—lung—esophageal cancer	0.000308	0.00526	CbGeAlD
Crizotinib—Febrile neutropenia—Methotrexate—esophageal cancer	0.000308	0.0109	CcSEcCtD
Crizotinib—JAK3—digestive system—esophageal cancer	0.000308	0.00525	CbGeAlD
Crizotinib—DCLK1—digestive system—esophageal cancer	0.000306	0.00522	CbGeAlD
Crizotinib—STK4—digestive system—esophageal cancer	0.000302	0.00515	CbGeAlD
Crizotinib—TESK1—trachea—esophageal cancer	0.0003	0.00511	CbGeAlD
Crizotinib—BMP2K—bronchus—esophageal cancer	0.000296	0.00506	CbGeAlD
Crizotinib—MET—lung—esophageal cancer	0.000291	0.00497	CbGeAlD
Crizotinib—RIPK2—epithelium—esophageal cancer	0.000288	0.00492	CbGeAlD
Crizotinib—EPHA5—digestive system—esophageal cancer	0.000285	0.00487	CbGeAlD
Crizotinib—ALK—digestive system—esophageal cancer	0.000285	0.00487	CbGeAlD
Crizotinib—LIMK2—trachea—esophageal cancer	0.000285	0.00487	CbGeAlD
Crizotinib—NUAK2—trachea—esophageal cancer	0.000284	0.00485	CbGeAlD
Crizotinib—RIPK2—bronchus—esophageal cancer	0.000284	0.00484	CbGeAlD
Crizotinib—ACVR1—trachea—esophageal cancer	0.000282	0.00481	CbGeAlD
Crizotinib—CDK7—lung—esophageal cancer	0.000282	0.00481	CbGeAlD
Crizotinib—PTK2B—smooth muscle tissue—esophageal cancer	0.00028	0.00478	CbGeAlD
Crizotinib—TAOK2—lung—esophageal cancer	0.00028	0.00477	CbGeAlD
Crizotinib—EPHA4—bronchus—esophageal cancer	0.000274	0.00468	CbGeAlD
Crizotinib—IGF1R—digestive system—esophageal cancer	0.000274	0.00468	CbGeAlD
Crizotinib—EPHA3—lung—esophageal cancer	0.000269	0.0046	CbGeAlD
Crizotinib—ACVR1B—lung—esophageal cancer	0.000269	0.0046	CbGeAlD
Crizotinib—PTK2—epithelium—esophageal cancer	0.000268	0.00457	CbGeAlD
Crizotinib—Burning sensation—Methotrexate—esophageal cancer	0.000267	0.00946	CcSEcCtD
Crizotinib—TBK1—bronchus—esophageal cancer	0.000264	0.0045	CbGeAlD
Crizotinib—PTK2—bronchus—esophageal cancer	0.000264	0.0045	CbGeAlD
Crizotinib—NEK9—lymph node—esophageal cancer	0.000263	0.00449	CbGeAlD
Crizotinib—Interstitial lung disease—Methotrexate—esophageal cancer	0.000262	0.00929	CcSEcCtD
Crizotinib—TYK2—bronchus—esophageal cancer	0.000262	0.00447	CbGeAlD
Crizotinib—AURKA—digestive system—esophageal cancer	0.00026	0.00444	CbGeAlD
Crizotinib—IRAK1—bronchus—esophageal cancer	0.000258	0.00441	CbGeAlD
Crizotinib—PTK2—smooth muscle tissue—esophageal cancer	0.000258	0.0044	CbGeAlD
Crizotinib—RPS6KB1—epithelium—esophageal cancer	0.000257	0.00439	CbGeAlD
Crizotinib—JAK3—lung—esophageal cancer	0.000257	0.00439	CbGeAlD
Crizotinib—TYK2—smooth muscle tissue—esophageal cancer	0.000256	0.00437	CbGeAlD
Crizotinib—DCLK1—lung—esophageal cancer	0.000255	0.00436	CbGeAlD
Crizotinib—Gait disturbance—Capecitabine—esophageal cancer	0.000255	0.00905	CcSEcCtD
Crizotinib—RIPK2—trachea—esophageal cancer	0.000255	0.00435	CbGeAlD
Crizotinib—PLK4—lung—esophageal cancer	0.000254	0.00433	CbGeAlD
Crizotinib—RPS6KB1—bronchus—esophageal cancer	0.000253	0.00433	CbGeAlD
Crizotinib—IRAK1—smooth muscle tissue—esophageal cancer	0.000253	0.00431	CbGeAlD
Crizotinib—STK4—lung—esophageal cancer	0.000252	0.0043	CbGeAlD
Crizotinib—LCK—bronchus—esophageal cancer	0.000252	0.0043	CbGeAlD
Crizotinib—Pulmonary embolism—Capecitabine—esophageal cancer	0.000249	0.00883	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.000249	0.00883	CcSEcCtD
Crizotinib—RPS6KB1—smooth muscle tissue—esophageal cancer	0.000248	0.00423	CbGeAlD
Crizotinib—EPHA4—trachea—esophageal cancer	0.000246	0.0042	CbGeAlD
Crizotinib—AXL—smooth muscle tissue—esophageal cancer	0.000246	0.00419	CbGeAlD
Crizotinib—EPHB4—epithelium—esophageal cancer	0.000244	0.00416	CbGeAlD
Crizotinib—JAK2—epithelium—esophageal cancer	0.000242	0.00413	CbGeAlD
Crizotinib—SLK—bronchus—esophageal cancer	0.000242	0.00412	CbGeAlD
Crizotinib—Hepatotoxicity—Methotrexate—esophageal cancer	0.00024	0.00852	CcSEcCtD
Crizotinib—EPHB4—bronchus—esophageal cancer	0.00024	0.00409	CbGeAlD
Crizotinib—PRKD1—lymph node—esophageal cancer	0.00024	0.00409	CbGeAlD
Crizotinib—EPHA2—epithelium—esophageal cancer	0.000239	0.00408	CbGeAlD
Crizotinib—ALK—lung—esophageal cancer	0.000238	0.00407	CbGeAlD
Crizotinib—FER—lung—esophageal cancer	0.000238	0.00407	CbGeAlD
Crizotinib—JAK2—bronchus—esophageal cancer	0.000238	0.00406	CbGeAlD
Crizotinib—Face oedema—Cisplatin—esophageal cancer	0.000237	0.0084	CcSEcCtD
Crizotinib—TBK1—trachea—esophageal cancer	0.000237	0.00404	CbGeAlD
Crizotinib—PTK2—trachea—esophageal cancer	0.000237	0.00404	CbGeAlD
Crizotinib—LIMK1—lymph node—esophageal cancer	0.000236	0.00404	CbGeAlD
Crizotinib—Fluid retention—Capecitabine—esophageal cancer	0.000236	0.00839	CcSEcCtD
Crizotinib—TNK1—lung—esophageal cancer	0.000236	0.00403	CbGeAlD
Crizotinib—EPHA2—bronchus—esophageal cancer	0.000235	0.00401	CbGeAlD
Crizotinib—TYK2—trachea—esophageal cancer	0.000235	0.00401	CbGeAlD
Crizotinib—EPHB4—smooth muscle tissue—esophageal cancer	0.000235	0.004	CbGeAlD
Crizotinib—Abscess—Methotrexate—esophageal cancer	0.000234	0.00831	CcSEcCtD
Crizotinib—Neuropathy—Capecitabine—esophageal cancer	0.000234	0.00829	CcSEcCtD
Crizotinib—MAP3K19—lung—esophageal cancer	0.000234	0.00399	CbGeAlD
Crizotinib—BMPR1B—lung—esophageal cancer	0.000234	0.00399	CbGeAlD
Crizotinib—MAP4K1—lung—esophageal cancer	0.000234	0.00399	CbGeAlD
Crizotinib—TEK—epithelium—esophageal cancer	0.000233	0.00398	CbGeAlD
Crizotinib—JAK2—smooth muscle tissue—esophageal cancer	0.000233	0.00398	CbGeAlD
Crizotinib—PRKD3—lymph node—esophageal cancer	0.00023	0.00393	CbGeAlD
Crizotinib—MAP4K5—bronchus—esophageal cancer	0.00023	0.00392	CbGeAlD
Crizotinib—TEK—bronchus—esophageal cancer	0.00023	0.00392	CbGeAlD
Crizotinib—MAP3K3—bronchus—esophageal cancer	0.00023	0.00392	CbGeAlD
Crizotinib—TNK2—lung—esophageal cancer	0.000229	0.00391	CbGeAlD
Crizotinib—IGF1R—lung—esophageal cancer	0.000229	0.00391	CbGeAlD
Crizotinib—RPS6KB1—trachea—esophageal cancer	0.000228	0.00388	CbGeAlD
Crizotinib—LCK—trachea—esophageal cancer	0.000226	0.00386	CbGeAlD
Crizotinib—MAP4K2—lung—esophageal cancer	0.000226	0.00385	CbGeAlD
Crizotinib—AXL—trachea—esophageal cancer	0.000225	0.00385	CbGeAlD
Crizotinib—DSTYK—lymph node—esophageal cancer	0.000225	0.00384	CbGeAlD
Crizotinib—MAP4K5—smooth muscle tissue—esophageal cancer	0.000225	0.00383	CbGeAlD
Crizotinib—TEK—smooth muscle tissue—esophageal cancer	0.000225	0.00383	CbGeAlD
Crizotinib—Hypokalaemia—Cisplatin—esophageal cancer	0.000223	0.00792	CcSEcCtD
Crizotinib—STK3—lung—esophageal cancer	0.000223	0.0038	CbGeAlD
Crizotinib—TIE1—lung—esophageal cancer	0.000223	0.0038	CbGeAlD
Crizotinib—BLK—lymph node—esophageal cancer	0.000222	0.00379	CbGeAlD
Crizotinib—PTK2B—digestive system—esophageal cancer	0.000221	0.00377	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000221	0.00783	CcSEcCtD
Crizotinib—LTK—lymph node—esophageal cancer	0.00022	0.00375	CbGeAlD
Crizotinib—CASK—lymph node—esophageal cancer	0.00022	0.00375	CbGeAlD
Crizotinib—EPHB6—bronchus—esophageal cancer	0.000219	0.00374	CbGeAlD
Crizotinib—RIPK2—digestive system—esophageal cancer	0.000219	0.00374	CbGeAlD
Crizotinib—AURKA—lung—esophageal cancer	0.000217	0.00371	CbGeAlD
Crizotinib—SLK—trachea—esophageal cancer	0.000217	0.0037	CbGeAlD
Crizotinib—Sepsis—Capecitabine—esophageal cancer	0.000216	0.00766	CcSEcCtD
Crizotinib—TESK1—lung—esophageal cancer	0.000215	0.00368	CbGeAlD
Crizotinib—EPHB4—trachea—esophageal cancer	0.000215	0.00367	CbGeAlD
Crizotinib—JAK2—trachea—esophageal cancer	0.000214	0.00365	CbGeAlD
Crizotinib—MAPK7—lymph node—esophageal cancer	0.000213	0.00363	CbGeAlD
Crizotinib—TXK—lymph node—esophageal cancer	0.000213	0.00363	CbGeAlD
Crizotinib—YES1—bronchus—esophageal cancer	0.000212	0.00362	CbGeAlD
Crizotinib—EPHA2—trachea—esophageal cancer	0.000211	0.0036	CbGeAlD
Crizotinib—FES—lymph node—esophageal cancer	0.000211	0.0036	CbGeAlD
Crizotinib—STK10—bronchus—esophageal cancer	0.00021	0.00358	CbGeAlD
Crizotinib—MERTK—lung—esophageal cancer	0.000209	0.00358	CbGeAlD
Crizotinib—TAOK3—bronchus—esophageal cancer	0.000209	0.00357	CbGeAlD
Crizotinib—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.000208	0.00737	CcSEcCtD
Crizotinib—YES1—smooth muscle tissue—esophageal cancer	0.000207	0.00354	CbGeAlD
Crizotinib—SRC—epithelium—esophageal cancer	0.000207	0.00353	CbGeAlD
Crizotinib—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000207	0.00734	CcSEcCtD
Crizotinib—MAP3K3—trachea—esophageal cancer	0.000206	0.00352	CbGeAlD
Crizotinib—MAP4K5—trachea—esophageal cancer	0.000206	0.00352	CbGeAlD
Crizotinib—LIMK2—lung—esophageal cancer	0.000205	0.0035	CbGeAlD
Crizotinib—NUAK2—lung—esophageal cancer	0.000204	0.00348	CbGeAlD
Crizotinib—PTK2—digestive system—esophageal cancer	0.000204	0.00347	CbGeAlD
Crizotinib—TBK1—digestive system—esophageal cancer	0.000204	0.00347	CbGeAlD
Crizotinib—MAP3K12—lung—esophageal cancer	0.000203	0.00346	CbGeAlD
Crizotinib—ACVR1—lung—esophageal cancer	0.000203	0.00346	CbGeAlD
Crizotinib—FLT3—lung—esophageal cancer	0.000203	0.00346	CbGeAlD
Crizotinib—TYK2—digestive system—esophageal cancer	0.000202	0.00345	CbGeAlD
Crizotinib—Hepatic failure—Capecitabine—esophageal cancer	0.000201	0.00713	CcSEcCtD
Crizotinib—SRC—smooth muscle tissue—esophageal cancer	0.0002	0.0034	CbGeAlD
Crizotinib—MET—lymph node—esophageal cancer	0.000199	0.0034	CbGeAlD
Crizotinib—STK35—lung—esophageal cancer	0.000199	0.00339	CbGeAlD
Crizotinib—EPHB6—trachea—esophageal cancer	0.000197	0.00336	CbGeAlD
Crizotinib—RPS6KB1—digestive system—esophageal cancer	0.000196	0.00334	CbGeAlD
Crizotinib—FGR—digestive system—esophageal cancer	0.000195	0.00332	CbGeAlD
Crizotinib—ABL2—lung—esophageal cancer	0.000194	0.0033	CbGeAlD
Crizotinib—CDK7—lymph node—esophageal cancer	0.000193	0.00329	CbGeAlD
Crizotinib—TAOK2—lymph node—esophageal cancer	0.000191	0.00326	CbGeAlD
Crizotinib—BMP2K—lung—esophageal cancer	0.000191	0.00326	CbGeAlD
Crizotinib—YES1—trachea—esophageal cancer	0.00019	0.00325	CbGeAlD
Crizotinib—Respiratory failure—Methotrexate—esophageal cancer	0.000189	0.0067	CcSEcCtD
Crizotinib—TAOK3—trachea—esophageal cancer	0.000188	0.00321	CbGeAlD
Crizotinib—Pulmonary embolism—Methotrexate—esophageal cancer	0.000185	0.00658	CcSEcCtD
Crizotinib—EPHB4—digestive system—esophageal cancer	0.000185	0.00316	CbGeAlD
Crizotinib—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000185	0.00657	CcSEcCtD
Crizotinib—PTK2B—lung—esophageal cancer	0.000185	0.00315	CbGeAlD
Crizotinib—EPHA3—lymph node—esophageal cancer	0.000184	0.00314	CbGeAlD
Crizotinib—ACVR1B—lymph node—esophageal cancer	0.000184	0.00314	CbGeAlD
Crizotinib—JAK2—digestive system—esophageal cancer	0.000184	0.00314	CbGeAlD
Crizotinib—RIPK2—lung—esophageal cancer	0.000183	0.00312	CbGeAlD
Crizotinib—CSF1R—bronchus—esophageal cancer	0.000183	0.00312	CbGeAlD
Crizotinib—EPHA2—digestive system—esophageal cancer	0.000182	0.0031	CbGeAlD
Crizotinib—Diplopia—Capecitabine—esophageal cancer	0.000181	0.00641	CcSEcCtD
Crizotinib—CSF1R—smooth muscle tissue—esophageal cancer	0.000179	0.00306	CbGeAlD
Crizotinib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000179	0.00634	CcSEcCtD
Crizotinib—EPHA4—lung—esophageal cancer	0.000177	0.00302	CbGeAlD
Crizotinib—JAK3—lymph node—esophageal cancer	0.000176	0.003	CbGeAlD
Crizotinib—DCLK1—lymph node—esophageal cancer	0.000175	0.00298	CbGeAlD
Crizotinib—Face oedema—Capecitabine—esophageal cancer	0.000174	0.00619	CcSEcCtD
Crizotinib—MAP3K2—lung—esophageal cancer	0.000174	0.00296	CbGeAlD
Crizotinib—PLK4—lymph node—esophageal cancer	0.000174	0.00296	CbGeAlD
Crizotinib—Bradycardia—Cisplatin—esophageal cancer	0.000173	0.00613	CcSEcCtD
Crizotinib—STK4—lymph node—esophageal cancer	0.000173	0.00294	CbGeAlD
Crizotinib—PTK2—lung—esophageal cancer	0.00017	0.0029	CbGeAlD
Crizotinib—TBK1—lung—esophageal cancer	0.00017	0.0029	CbGeAlD
Crizotinib—TYK2—lung—esophageal cancer	0.000169	0.00288	CbGeAlD
Crizotinib—Urinary tract disorder—Cisplatin—esophageal cancer	0.000167	0.00594	CcSEcCtD
Crizotinib—IRAK1—lung—esophageal cancer	0.000167	0.00284	CbGeAlD
Crizotinib—Urethral disorder—Cisplatin—esophageal cancer	0.000166	0.0059	CcSEcCtD
Crizotinib—Hypokalaemia—Capecitabine—esophageal cancer	0.000164	0.00584	CcSEcCtD
Crizotinib—CSF1R—trachea—esophageal cancer	0.000164	0.00281	CbGeAlD
Crizotinib—YES1—digestive system—esophageal cancer	0.000164	0.00279	CbGeAlD
Crizotinib—RPS6KB1—lung—esophageal cancer	0.000164	0.00279	CbGeAlD
Crizotinib—Visual impairment—Cisplatin—esophageal cancer	0.000163	0.0058	CcSEcCtD
Crizotinib—FER—lymph node—esophageal cancer	0.000163	0.00278	CbGeAlD
Crizotinib—ALK—lymph node—esophageal cancer	0.000163	0.00278	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000163	0.00577	CcSEcCtD
Crizotinib—FGR—lung—esophageal cancer	0.000163	0.00277	CbGeAlD
Crizotinib—LCK—lung—esophageal cancer	0.000163	0.00277	CbGeAlD
Crizotinib—STK10—digestive system—esophageal cancer	0.000162	0.00277	CbGeAlD
Crizotinib—AXL—lung—esophageal cancer	0.000162	0.00276	CbGeAlD
Crizotinib—TAOK3—digestive system—esophageal cancer	0.000162	0.00276	CbGeAlD
Crizotinib—TNK1—lymph node—esophageal cancer	0.000161	0.00275	CbGeAlD
Crizotinib—Sepsis—Methotrexate—esophageal cancer	0.000161	0.00571	CcSEcCtD
Crizotinib—MAP4K1—lymph node—esophageal cancer	0.00016	0.00273	CbGeAlD
Crizotinib—BMPR1B—lymph node—esophageal cancer	0.00016	0.00273	CbGeAlD
Crizotinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000159	0.00565	CcSEcCtD
Crizotinib—Muscular weakness—Capecitabine—esophageal cancer	0.000159	0.00565	CcSEcCtD
Crizotinib—Eye disorder—Cisplatin—esophageal cancer	0.000158	0.00562	CcSEcCtD
Crizotinib—SRC—digestive system—esophageal cancer	0.000158	0.00269	CbGeAlD
Crizotinib—Cardiac disorder—Cisplatin—esophageal cancer	0.000157	0.00558	CcSEcCtD
Crizotinib—IGF1R—lymph node—esophageal cancer	0.000157	0.00267	CbGeAlD
Crizotinib—TNK2—lymph node—esophageal cancer	0.000157	0.00267	CbGeAlD
Crizotinib—SLK—lung—esophageal cancer	0.000156	0.00266	CbGeAlD
Crizotinib—EPHB4—lung—esophageal cancer	0.000155	0.00264	CbGeAlD
Crizotinib—MAP4K2—lymph node—esophageal cancer	0.000154	0.00264	CbGeAlD
Crizotinib—JAK2—lung—esophageal cancer	0.000154	0.00262	CbGeAlD
Crizotinib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000153	0.00542	CcSEcCtD
Crizotinib—STK3—lymph node—esophageal cancer	0.000152	0.0026	CbGeAlD
Crizotinib—TIE1—lymph node—esophageal cancer	0.000152	0.0026	CbGeAlD
Crizotinib—EPHA2—lung—esophageal cancer	0.000152	0.00259	CbGeAlD
Crizotinib—Arrhythmia—Cisplatin—esophageal cancer	0.000151	0.00538	CcSEcCtD
Crizotinib—Hepatic failure—Methotrexate—esophageal cancer	0.00015	0.00531	CcSEcCtD
Crizotinib—AURKA—lymph node—esophageal cancer	0.000149	0.00253	CbGeAlD
Crizotinib—MAP4K5—lung—esophageal cancer	0.000148	0.00253	CbGeAlD
Crizotinib—TEK—lung—esophageal cancer	0.000148	0.00253	CbGeAlD
Crizotinib—MAP3K3—lung—esophageal cancer	0.000148	0.00253	CbGeAlD
Crizotinib—Malnutrition—Cisplatin—esophageal cancer	0.000148	0.00524	CcSEcCtD
Crizotinib—TESK1—lymph node—esophageal cancer	0.000147	0.00251	CbGeAlD
Crizotinib—Neutropenia—Capecitabine—esophageal cancer	0.000146	0.00518	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000145	0.00515	CcSEcCtD
Crizotinib—ABL1—bronchus—esophageal cancer	0.000145	0.00247	CbGeAlD
Crizotinib—MERTK—lymph node—esophageal cancer	0.000143	0.00245	CbGeAlD
Crizotinib—Visual disturbance—Methotrexate—esophageal cancer	0.000142	0.00504	CcSEcCtD
Crizotinib—ABL1—smooth muscle tissue—esophageal cancer	0.000142	0.00242	CbGeAlD
Crizotinib—EPHB6—lung—esophageal cancer	0.000142	0.00241	CbGeAlD
Crizotinib—CSF1R—digestive system—esophageal cancer	0.000141	0.00241	CbGeAlD
Crizotinib—Weight decreased—Capecitabine—esophageal cancer	0.000141	0.00501	CcSEcCtD
Crizotinib—LIMK2—lymph node—esophageal cancer	0.00014	0.00239	CbGeAlD
Crizotinib—Pneumonia—Capecitabine—esophageal cancer	0.00014	0.00497	CcSEcCtD
Crizotinib—NUAK2—lymph node—esophageal cancer	0.00014	0.00238	CbGeAlD
Crizotinib—Infestation—Capecitabine—esophageal cancer	0.000139	0.00494	CcSEcCtD
Crizotinib—Infestation NOS—Capecitabine—esophageal cancer	0.000139	0.00494	CcSEcCtD
Crizotinib—Vision blurred—Cisplatin—esophageal cancer	0.000139	0.00494	CcSEcCtD
Crizotinib—ACVR1—lymph node—esophageal cancer	0.000139	0.00237	CbGeAlD
Crizotinib—MAP3K12—lymph node—esophageal cancer	0.000139	0.00237	CbGeAlD
Crizotinib—FLT3—lymph node—esophageal cancer	0.000139	0.00237	CbGeAlD
Crizotinib—YES1—lung—esophageal cancer	0.000137	0.00233	CbGeAlD
Crizotinib—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000136	0.00484	CcSEcCtD
Crizotinib—Anaemia—Cisplatin—esophageal cancer	0.000136	0.00484	CcSEcCtD
Crizotinib—STK35—lymph node—esophageal cancer	0.000136	0.00232	CbGeAlD
Crizotinib—STK10—lung—esophageal cancer	0.000136	0.00231	CbGeAlD
Crizotinib—TAOK3—lung—esophageal cancer	0.000135	0.0023	CbGeAlD
Crizotinib—ABL2—lymph node—esophageal cancer	0.000132	0.00226	CbGeAlD
Crizotinib—Leukopenia—Cisplatin—esophageal cancer	0.000132	0.00469	CcSEcCtD
Crizotinib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000132	0.00467	CcSEcCtD
Crizotinib—SRC—lung—esophageal cancer	0.000132	0.00225	CbGeAlD
Crizotinib—BMP2K—lymph node—esophageal cancer	0.000131	0.00223	CbGeAlD
Crizotinib—ABL1—trachea—esophageal cancer	0.00013	0.00222	CbGeAlD
Crizotinib—Bradycardia—Capecitabine—esophageal cancer	0.000127	0.00452	CcSEcCtD
Crizotinib—PTK2B—lymph node—esophageal cancer	0.000126	0.00215	CbGeAlD
Crizotinib—RIPK2—lymph node—esophageal cancer	0.000125	0.00214	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000125	0.00443	CcSEcCtD
Crizotinib—Hypoaesthesia—Capecitabine—esophageal cancer	0.000124	0.00441	CcSEcCtD
Crizotinib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000123	0.00438	CcSEcCtD
Crizotinib—Oedema peripheral—Capecitabine—esophageal cancer	0.000123	0.00437	CcSEcCtD
Crizotinib—Urethral disorder—Capecitabine—esophageal cancer	0.000123	0.00435	CcSEcCtD
Crizotinib—EPHA4—lymph node—esophageal cancer	0.000121	0.00207	CbGeAlD
Crizotinib—Oedema—Cisplatin—esophageal cancer	0.00012	0.00427	CcSEcCtD
Crizotinib—Visual impairment—Capecitabine—esophageal cancer	0.00012	0.00427	CcSEcCtD
Crizotinib—Infection—Cisplatin—esophageal cancer	0.00012	0.00425	CcSEcCtD
Crizotinib—MAP3K2—lymph node—esophageal cancer	0.000119	0.00203	CbGeAlD
Crizotinib—Nervous system disorder—Cisplatin—esophageal cancer	0.000118	0.00419	CcSEcCtD
Crizotinib—CSF1R—lung—esophageal cancer	0.000118	0.00202	CbGeAlD
Crizotinib—Skin disorder—Cisplatin—esophageal cancer	0.000117	0.00415	CcSEcCtD
Crizotinib—Eye disorder—Capecitabine—esophageal cancer	0.000117	0.00415	CcSEcCtD
Crizotinib—PTK2—lymph node—esophageal cancer	0.000116	0.00198	CbGeAlD
Crizotinib—TBK1—lymph node—esophageal cancer	0.000116	0.00198	CbGeAlD
Crizotinib—Cardiac disorder—Capecitabine—esophageal cancer	0.000116	0.00412	CcSEcCtD
Crizotinib—TYK2—lymph node—esophageal cancer	0.000115	0.00197	CbGeAlD
Crizotinib—IRAK1—lymph node—esophageal cancer	0.000114	0.00195	CbGeAlD
Crizotinib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000113	0.004	CcSEcCtD
Crizotinib—RPS6KB1—lymph node—esophageal cancer	0.000112	0.00191	CbGeAlD
Crizotinib—ABL1—digestive system—esophageal cancer	0.000112	0.00191	CbGeAlD
Crizotinib—Arrhythmia—Capecitabine—esophageal cancer	0.000112	0.00396	CcSEcCtD
Crizotinib—LCK—lymph node—esophageal cancer	0.000111	0.0019	CbGeAlD
Crizotinib—FGR—lymph node—esophageal cancer	0.000111	0.0019	CbGeAlD
Crizotinib—AXL—lymph node—esophageal cancer	0.000111	0.00189	CbGeAlD
Crizotinib—Malnutrition—Capecitabine—esophageal cancer	0.000109	0.00386	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—esophageal cancer	0.000109	0.00386	CcSEcCtD
Crizotinib—Paraesthesia—Cisplatin—esophageal cancer	0.000108	0.00384	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000108	0.00383	CcSEcCtD
Crizotinib—Dyspnoea—Cisplatin—esophageal cancer	0.000107	0.00381	CcSEcCtD
Crizotinib—SLK—lymph node—esophageal cancer	0.000107	0.00182	CbGeAlD
Crizotinib—Dysgeusia—Capecitabine—esophageal cancer	0.000107	0.00378	CcSEcCtD
Crizotinib—EPHB4—lymph node—esophageal cancer	0.000106	0.00181	CbGeAlD
Crizotinib—JAK2—lymph node—esophageal cancer	0.000105	0.00179	CbGeAlD
Crizotinib—Decreased appetite—Cisplatin—esophageal cancer	0.000105	0.00372	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—esophageal cancer	0.000104	0.0037	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000104	0.00369	CcSEcCtD
Crizotinib—EPHA2—lymph node—esophageal cancer	0.000104	0.00177	CbGeAlD
Crizotinib—Infestation—Methotrexate—esophageal cancer	0.000104	0.00368	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—esophageal cancer	0.000104	0.00368	CcSEcCtD
Crizotinib—Vision blurred—Capecitabine—esophageal cancer	0.000103	0.00364	CcSEcCtD
Crizotinib—TEK—lymph node—esophageal cancer	0.000101	0.00173	CbGeAlD
Crizotinib—MAP3K3—lymph node—esophageal cancer	0.000101	0.00173	CbGeAlD
Crizotinib—MAP4K5—lymph node—esophageal cancer	0.000101	0.00173	CbGeAlD
Crizotinib—Anaemia—Capecitabine—esophageal cancer	0.000101	0.00357	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—esophageal cancer	9.8e-05	0.00348	CcSEcCtD
Crizotinib—Syncope—Capecitabine—esophageal cancer	9.76e-05	0.00346	CcSEcCtD
Crizotinib—Leukopenia—Capecitabine—esophageal cancer	9.74e-05	0.00346	CcSEcCtD
Crizotinib—EPHB6—lymph node—esophageal cancer	9.68e-05	0.00165	CbGeAlD
Crizotinib—Loss of consciousness—Capecitabine—esophageal cancer	9.56e-05	0.00339	CcSEcCtD
Crizotinib—Body temperature increased—Cisplatin—esophageal cancer	9.52e-05	0.00338	CcSEcCtD
Crizotinib—YES1—lymph node—esophageal cancer	9.35e-05	0.0016	CbGeAlD
Crizotinib—ABL1—lung—esophageal cancer	9.34e-05	0.00159	CbGeAlD
Crizotinib—STK10—lymph node—esophageal cancer	9.27e-05	0.00158	CbGeAlD
Crizotinib—TAOK3—lymph node—esophageal cancer	9.23e-05	0.00158	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	9.2e-05	0.00326	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—esophageal cancer	9.19e-05	0.00326	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—esophageal cancer	9.12e-05	0.00324	CcSEcCtD
Crizotinib—SRC—lymph node—esophageal cancer	9e-05	0.00154	CbGeAlD
Crizotinib—Visual impairment—Methotrexate—esophageal cancer	8.97e-05	0.00318	CcSEcCtD
Crizotinib—Oedema—Capecitabine—esophageal cancer	8.88e-05	0.00315	CcSEcCtD
Crizotinib—Infection—Capecitabine—esophageal cancer	8.82e-05	0.00313	CcSEcCtD
Crizotinib—Shock—Capecitabine—esophageal cancer	8.74e-05	0.0031	CcSEcCtD
Crizotinib—Nervous system disorder—Capecitabine—esophageal cancer	8.71e-05	0.00309	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—esophageal cancer	8.7e-05	0.00309	CcSEcCtD
Crizotinib—Asthenia—Cisplatin—esophageal cancer	8.64e-05	0.00307	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—esophageal cancer	8.64e-05	0.00306	CcSEcCtD
Crizotinib—Skin disorder—Capecitabine—esophageal cancer	8.63e-05	0.00306	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—esophageal cancer	8.39e-05	0.00298	CcSEcCtD
Crizotinib—Diarrhoea—Cisplatin—esophageal cancer	8.24e-05	0.00292	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—esophageal cancer	8.1e-05	0.00287	CcSEcCtD
Crizotinib—CSF1R—lymph node—esophageal cancer	8.08e-05	0.00138	CbGeAlD
Crizotinib—Paraesthesia—Capecitabine—esophageal cancer	7.97e-05	0.00283	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—esophageal cancer	7.93e-05	0.00281	CcSEcCtD
Crizotinib—Dyspnoea—Capecitabine—esophageal cancer	7.92e-05	0.00281	CcSEcCtD
Crizotinib—Dyspepsia—Capecitabine—esophageal cancer	7.82e-05	0.00277	CcSEcCtD
Crizotinib—Decreased appetite—Capecitabine—esophageal cancer	7.72e-05	0.00274	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	7.67e-05	0.00272	CcSEcCtD
Crizotinib—Vomiting—Cisplatin—esophageal cancer	7.66e-05	0.00272	CcSEcCtD
Crizotinib—Fatigue—Capecitabine—esophageal cancer	7.66e-05	0.00272	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—esophageal cancer	7.63e-05	0.00271	CcSEcCtD
Crizotinib—Rash—Cisplatin—esophageal cancer	7.6e-05	0.0027	CcSEcCtD
Crizotinib—Constipation—Capecitabine—esophageal cancer	7.59e-05	0.00269	CcSEcCtD
Crizotinib—Dermatitis—Cisplatin—esophageal cancer	7.59e-05	0.00269	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—esophageal cancer	7.49e-05	0.00266	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—esophageal cancer	7.25e-05	0.00257	CcSEcCtD
Crizotinib—Nausea—Cisplatin—esophageal cancer	7.16e-05	0.00254	CcSEcCtD
Crizotinib—Body temperature increased—Capecitabine—esophageal cancer	7.02e-05	0.00249	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	6.85e-05	0.00243	CcSEcCtD
Crizotinib—Infection—Methotrexate—esophageal cancer	6.57e-05	0.00233	CcSEcCtD
Crizotinib—CYP3A5—digestive system—esophageal cancer	6.54e-05	0.00112	CbGeAlD
Crizotinib—Nervous system disorder—Methotrexate—esophageal cancer	6.48e-05	0.0023	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—esophageal cancer	6.42e-05	0.00228	CcSEcCtD
Crizotinib—ABL1—lymph node—esophageal cancer	6.39e-05	0.00109	CbGeAlD
Crizotinib—Asthenia—Capecitabine—esophageal cancer	6.37e-05	0.00226	CcSEcCtD
Crizotinib—Diarrhoea—Capecitabine—esophageal cancer	6.08e-05	0.00216	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—esophageal cancer	5.94e-05	0.00211	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—esophageal cancer	5.89e-05	0.00209	CcSEcCtD
Crizotinib—Dizziness—Capecitabine—esophageal cancer	5.87e-05	0.00208	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—esophageal cancer	5.82e-05	0.00206	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—esophageal cancer	5.75e-05	0.00204	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	5.71e-05	0.00203	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—esophageal cancer	5.7e-05	0.00202	CcSEcCtD
Crizotinib—Vomiting—Capecitabine—esophageal cancer	5.65e-05	0.002	CcSEcCtD
Crizotinib—Rash—Capecitabine—esophageal cancer	5.6e-05	0.00199	CcSEcCtD
Crizotinib—Dermatitis—Capecitabine—esophageal cancer	5.59e-05	0.00199	CcSEcCtD
Crizotinib—CYP3A5—lung—esophageal cancer	5.47e-05	0.000933	CbGeAlD
Crizotinib—Nausea—Capecitabine—esophageal cancer	5.27e-05	0.00187	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—esophageal cancer	5.23e-05	0.00185	CcSEcCtD
Crizotinib—CYP3A4—digestive system—esophageal cancer	4.91e-05	0.000838	CbGeAlD
Crizotinib—Asthenia—Methotrexate—esophageal cancer	4.74e-05	0.00168	CcSEcCtD
Crizotinib—ABCB1—epithelium—esophageal cancer	4.57e-05	0.00078	CbGeAlD
Crizotinib—Diarrhoea—Methotrexate—esophageal cancer	4.52e-05	0.00161	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—esophageal cancer	4.37e-05	0.00155	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—esophageal cancer	4.2e-05	0.00149	CcSEcCtD
Crizotinib—Rash—Methotrexate—esophageal cancer	4.17e-05	0.00148	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—esophageal cancer	4.16e-05	0.00148	CcSEcCtD
Crizotinib—ABCB1—trachea—esophageal cancer	4.04e-05	0.00069	CbGeAlD
Crizotinib—Nausea—Methotrexate—esophageal cancer	3.93e-05	0.00139	CcSEcCtD
Crizotinib—ABCB1—digestive system—esophageal cancer	3.48e-05	0.000593	CbGeAlD
Crizotinib—ABCB1—lung—esophageal cancer	2.9e-05	0.000495	CbGeAlD
Crizotinib—ABCB1—lymph node—esophageal cancer	1.99e-05	0.000339	CbGeAlD
Crizotinib—PTK2B—Signaling Pathways—CDKN1A—esophageal cancer	8.94e-07	8.52e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EGFR—esophageal cancer	8.93e-07	8.51e-06	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—PIK3CA—esophageal cancer	8.91e-07	8.49e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NOS3—esophageal cancer	8.9e-07	8.49e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EGFR—esophageal cancer	8.87e-07	8.46e-06	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—EGFR—esophageal cancer	8.87e-07	8.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—ERBB2—esophageal cancer	8.87e-07	8.45e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CCND1—esophageal cancer	8.85e-07	8.43e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—EGFR—esophageal cancer	8.81e-07	8.39e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—EP300—esophageal cancer	8.78e-07	8.37e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NOS3—esophageal cancer	8.78e-07	8.37e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS3—esophageal cancer	8.75e-07	8.34e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EP300—esophageal cancer	8.63e-07	8.23e-06	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—esophageal cancer	8.62e-07	8.22e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CCND1—esophageal cancer	8.58e-07	8.18e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KDR—esophageal cancer	8.56e-07	8.16e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTT1—esophageal cancer	8.56e-07	8.16e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CREBBP—esophageal cancer	8.56e-07	8.16e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CDKN1A—esophageal cancer	8.56e-07	8.16e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EP300—esophageal cancer	8.51e-07	8.11e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP19A1—esophageal cancer	8.5e-07	8.1e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP2A6—esophageal cancer	8.46e-07	8.07e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS2—esophageal cancer	8.44e-07	8.05e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MYC—esophageal cancer	8.44e-07	8.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFBR2—esophageal cancer	8.39e-07	8e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HIF1A—esophageal cancer	8.38e-07	7.99e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NOTCH1—esophageal cancer	8.36e-07	7.97e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EGFR—esophageal cancer	8.35e-07	7.96e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOS3—esophageal cancer	8.33e-07	7.94e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—ERBB2—esophageal cancer	8.33e-07	7.94e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CDKN1A—esophageal cancer	8.3e-07	7.91e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—esophageal cancer	8.25e-07	7.87e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CASP8—esophageal cancer	8.25e-07	7.86e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—ERBB2—esophageal cancer	8.21e-07	7.83e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CREBBP—esophageal cancer	8.21e-07	7.82e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—ERBB2—esophageal cancer	8.19e-07	7.8e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—esophageal cancer	8.18e-07	7.8e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EP300—esophageal cancer	8.14e-07	7.76e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—esophageal cancer	8.11e-07	7.73e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—CDKN1A—esophageal cancer	8.1e-07	7.72e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOS3—esophageal cancer	8.09e-07	7.71e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOTCH1—esophageal cancer	8.07e-07	7.69e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CDKN1A—esophageal cancer	8.06e-07	7.68e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS1—esophageal cancer	8.02e-07	7.65e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ENO1—esophageal cancer	8.02e-07	7.65e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—PIK3CA—esophageal cancer	8.02e-07	7.65e-06	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	8.02e-07	7.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KDR—esophageal cancer	8.01e-07	7.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—esophageal cancer	8e-07	7.63e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—BCL2—esophageal cancer	7.99e-07	7.62e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SMAD4—esophageal cancer	7.94e-07	7.57e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PSME1—esophageal cancer	7.91e-07	7.54e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PSME2—esophageal cancer	7.91e-07	7.54e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EP300—esophageal cancer	7.9e-07	7.53e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—PIK3CA—esophageal cancer	7.89e-07	7.52e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADH1B—esophageal cancer	7.87e-07	7.5e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—esophageal cancer	7.86e-07	7.49e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ERBB2—esophageal cancer	7.79e-07	7.43e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—ERBB2—esophageal cancer	7.77e-07	7.4e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—HMOX1—esophageal cancer	7.76e-07	7.39e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—PIK3CA—esophageal cancer	7.75e-07	7.39e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—EP300—esophageal cancer	7.7e-07	7.34e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—PIK3CA—esophageal cancer	7.7e-07	7.34e-06	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—PIK3CA—esophageal cancer	7.7e-07	7.34e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EP300—esophageal cancer	7.67e-07	7.31e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS3—esophageal cancer	7.66e-07	7.31e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—MYC—esophageal cancer	7.65e-07	7.3e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—PIK3CA—esophageal cancer	7.64e-07	7.29e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—esophageal cancer	7.63e-07	7.27e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CREBBP—esophageal cancer	7.58e-07	7.22e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CDKN1A—esophageal cancer	7.58e-07	7.22e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ERBB2—esophageal cancer	7.56e-07	7.21e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOTCH1—esophageal cancer	7.55e-07	7.2e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TYMP—esophageal cancer	7.52e-07	7.17e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MYC—esophageal cancer	7.52e-07	7.17e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—esophageal cancer	7.49e-07	7.14e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ABCB1—esophageal cancer	7.45e-07	7.1e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MYC—esophageal cancer	7.41e-07	7.07e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCND1—esophageal cancer	7.36e-07	7.01e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—esophageal cancer	7.36e-07	7.01e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HIF1A—esophageal cancer	7.34e-07	7e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	7.32e-07	6.98e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CREBBP—esophageal cancer	7.31e-07	6.97e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCND1—esophageal cancer	7.26e-07	6.92e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—esophageal cancer	7.25e-07	6.91e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—PIK3CA—esophageal cancer	7.25e-07	6.91e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EP300—esophageal cancer	7.21e-07	6.87e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—ERBB2—esophageal cancer	7.17e-07	6.83e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—PIK3CA—esophageal cancer	7.16e-07	6.83e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	7.13e-07	6.8e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CDKN1A—esophageal cancer	7.12e-07	6.79e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—PIK3CA—esophageal cancer	7.1e-07	6.77e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MYC—esophageal cancer	7.09e-07	6.76e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—BCL2—esophageal cancer	7.08e-07	6.74e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—PIK3CA—esophageal cancer	7.04e-07	6.71e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CDKN1A—esophageal cancer	7.02e-07	6.69e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KDR—esophageal cancer	7.02e-07	6.69e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—esophageal cancer	7.01e-07	6.68e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—CDKN1A—esophageal cancer	7e-07	6.67e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—esophageal cancer	6.94e-07	6.61e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—esophageal cancer	6.93e-07	6.61e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCND1—esophageal cancer	6.88e-07	6.56e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MYC—esophageal cancer	6.88e-07	6.56e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB2—esophageal cancer	6.87e-07	6.55e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CREBBP—esophageal cancer	6.84e-07	6.52e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP1B1—esophageal cancer	6.82e-07	6.5e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—PIK3CA—esophageal cancer	6.82e-07	6.5e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	6.8e-07	6.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TPI1—esophageal cancer	6.8e-07	6.49e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS3—esophageal cancer	6.79e-07	6.47e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EP300—esophageal cancer	6.77e-07	6.46e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—esophageal cancer	6.73e-07	6.41e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—esophageal cancer	6.73e-07	6.41e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCND1—esophageal cancer	6.68e-07	6.37e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EP300—esophageal cancer	6.68e-07	6.37e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CDKN1A—esophageal cancer	6.66e-07	6.35e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EP300—esophageal cancer	6.66e-07	6.35e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDKN1A—esophageal cancer	6.64e-07	6.33e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOTCH1—esophageal cancer	6.61e-07	6.3e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—esophageal cancer	6.57e-07	6.26e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—esophageal cancer	6.55e-07	6.24e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—esophageal cancer	6.54e-07	6.23e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	6.52e-07	6.22e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—PIK3CA—esophageal cancer	6.5e-07	6.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HIF1A—esophageal cancer	6.5e-07	6.19e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDKN1A—esophageal cancer	6.46e-07	6.16e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—PIK3CA—esophageal cancer	6.43e-07	6.13e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP19A1—esophageal cancer	6.41e-07	6.11e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PIK3CA—esophageal cancer	6.39e-07	6.09e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB2—esophageal cancer	6.35e-07	6.05e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EP300—esophageal cancer	6.34e-07	6.04e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EP300—esophageal cancer	6.31e-07	6.02e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PIK3CA—esophageal cancer	6.29e-07	6e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	6.28e-07	5.99e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	6.22e-07	5.93e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KDR—esophageal cancer	6.21e-07	5.92e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—esophageal cancer	6.21e-07	5.92e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—esophageal cancer	6.18e-07	5.89e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EP300—esophageal cancer	6.15e-07	5.86e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—esophageal cancer	6.15e-07	5.86e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—esophageal cancer	6.13e-07	5.84e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1A—esophageal cancer	6.13e-07	5.84e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—esophageal cancer	6.12e-07	5.84e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—esophageal cancer	6.09e-07	5.8e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PIK3CA—esophageal cancer	6.02e-07	5.74e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CREBBP—esophageal cancer	5.99e-07	5.71e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNG7—esophageal cancer	5.92e-07	5.64e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—esophageal cancer	5.9e-07	5.63e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1A—esophageal cancer	5.88e-07	5.6e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HMOX1—esophageal cancer	5.85e-07	5.58e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOTCH1—esophageal cancer	5.85e-07	5.58e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PIK3CA—esophageal cancer	5.84e-07	5.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PIK3CA—esophageal cancer	5.84e-07	5.56e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EP300—esophageal cancer	5.83e-07	5.56e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—esophageal cancer	5.83e-07	5.55e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—esophageal cancer	5.82e-07	5.55e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—esophageal cancer	5.8e-07	5.53e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—esophageal cancer	5.77e-07	5.5e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—esophageal cancer	5.73e-07	5.46e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—PIK3CA—esophageal cancer	5.7e-07	5.43e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—esophageal cancer	5.69e-07	5.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—esophageal cancer	5.67e-07	5.41e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PIK3CA—esophageal cancer	5.67e-07	5.41e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—esophageal cancer	5.65e-07	5.39e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EP300—esophageal cancer	5.59e-07	5.33e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.55e-07	5.29e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—esophageal cancer	5.52e-07	5.26e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—esophageal cancer	5.42e-07	5.17e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—esophageal cancer	5.41e-07	5.16e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—esophageal cancer	5.4e-07	5.15e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—esophageal cancer	5.38e-07	5.13e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—esophageal cancer	5.37e-07	5.12e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—esophageal cancer	5.36e-07	5.11e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—esophageal cancer	5.33e-07	5.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CREBBP—esophageal cancer	5.31e-07	5.06e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.28e-07	5.03e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—esophageal cancer	5.24e-07	5e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—esophageal cancer	5.23e-07	4.99e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.21e-07	4.97e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—esophageal cancer	5.16e-07	4.92e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—esophageal cancer	5.08e-07	4.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—esophageal cancer	5.06e-07	4.83e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—esophageal cancer	5.02e-07	4.79e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—esophageal cancer	5.01e-07	4.78e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—esophageal cancer	4.98e-07	4.75e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CREBBP—esophageal cancer	4.98e-07	4.74e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—esophageal cancer	4.97e-07	4.74e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO1—esophageal cancer	4.94e-07	4.71e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.94e-07	4.71e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—esophageal cancer	4.94e-07	4.71e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—esophageal cancer	4.92e-07	4.69e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—esophageal cancer	4.9e-07	4.67e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PSME1—esophageal cancer	4.87e-07	4.64e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PSME2—esophageal cancer	4.87e-07	4.64e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—esophageal cancer	4.85e-07	4.62e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—esophageal cancer	4.78e-07	4.56e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—esophageal cancer	4.76e-07	4.54e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—esophageal cancer	4.75e-07	4.53e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—esophageal cancer	4.69e-07	4.47e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—esophageal cancer	4.67e-07	4.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—esophageal cancer	4.66e-07	4.44e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—esophageal cancer	4.55e-07	4.34e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—esophageal cancer	4.53e-07	4.32e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—esophageal cancer	4.5e-07	4.29e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—esophageal cancer	4.46e-07	4.25e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—esophageal cancer	4.44e-07	4.24e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—esophageal cancer	4.44e-07	4.23e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—esophageal cancer	4.4e-07	4.2e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—esophageal cancer	4.4e-07	4.19e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—esophageal cancer	4.34e-07	4.14e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—esophageal cancer	4.31e-07	4.11e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—esophageal cancer	4.29e-07	4.09e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—esophageal cancer	4.25e-07	4.05e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.2e-07	4.01e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—esophageal cancer	4.14e-07	3.94e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—esophageal cancer	4.08e-07	3.89e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—esophageal cancer	4.07e-07	3.88e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—esophageal cancer	4.06e-07	3.87e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—esophageal cancer	3.97e-07	3.79e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.95e-07	3.77e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—esophageal cancer	3.93e-07	3.74e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—esophageal cancer	3.82e-07	3.64e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—esophageal cancer	3.8e-07	3.62e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CREBBP—esophageal cancer	3.75e-07	3.58e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—esophageal cancer	3.68e-07	3.51e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—esophageal cancer	3.61e-07	3.45e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.61e-07	3.44e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—esophageal cancer	3.56e-07	3.4e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—esophageal cancer	3.56e-07	3.39e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—esophageal cancer	3.48e-07	3.32e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.46e-07	3.3e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—esophageal cancer	3.45e-07	3.29e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—esophageal cancer	3.39e-07	3.23e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—esophageal cancer	3.36e-07	3.2e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—esophageal cancer	3.34e-07	3.18e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—esophageal cancer	3.15e-07	3e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—esophageal cancer	3.08e-07	2.94e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—esophageal cancer	3.07e-07	2.93e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—esophageal cancer	3.02e-07	2.88e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—esophageal cancer	2.92e-07	2.79e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—esophageal cancer	2.67e-07	2.55e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—esophageal cancer	2.59e-07	2.47e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—esophageal cancer	2.56e-07	2.44e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—esophageal cancer	2.51e-07	2.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.31e-07	2.21e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—esophageal cancer	2.07e-07	1.97e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.89e-07	1.81e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.89e-07	1.8e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—esophageal cancer	1.58e-07	1.5e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.17e-07	1.11e-06	CbGpPWpGaD
